{'fraction_non_alphanumeric': 0.024165707710011506, 'fraction_numerical': 0.006904487917146145, 'mean_word_length': 5.641221374045801, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’

The development of non-peptide receptor antagonists for angiotensin I1 (AngII) has opened new therapeutic possibilities in several cardiovascular diseases. It has also stimulated considerable research into fundamental aspects of the pharmacology and physiology of AngII, from the molecular level through to clinical aspects. AT, receptors were the focus of a symposium organized by the Baker Medical Research Institute in Melbourne, Australia, in December 1995. The symposium was part of the Institute’s series of annual scientific meetings. The organizing Committee for the meeting was Warwick Anderson, Garry Jennings, John Funder, Alex Bobik, Stephen Harrap and John Shaw. All papers published have been reviewed via the usual peer review processes of this journal.